Physicians' Academy for Cardiovascular Education

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

The Clinical Unmet need in the patient with Diabetes and ACS

Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

How incretin therapy changes diabetes and prediabetes management

May 22, 2017

Challenges in Heart Failure management: Diabetes and Renal Impairment

May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

GLP-1 receptor agonist approved by FDA for treatment of T2DM

Dec. 12, 2017 - news

Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.

First time randomized trial shows remission of T2DM with dietary and lifestyle intervention

Dec. 11, 2017 - Lean MEJ et al., - The Lancet, 2017
The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK
Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Prof. John Deanfield states that the introduction of two new drug classes with CV benefits can really make a difference for the CV outcomes of high-risk diabetic patients

Greater absolute benefit of SGLT2 inhibitor in secondary vs primary prevention in T2DM

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Kenneth Mahaffey (Stanford Center for Clinical Research, Stanford, CA, USA)

Nov. 20, 2017 - news

AHA 2017 Analysis of CANVAS program compared use of canagliflozin in primary or secondary prevention and found a greater benefit on CV, renal and death outcomes in those with existing CVD.

Meeting Impression | Managing Diabetes & CVD: Is epigenetics a new way forward?

August 26, 2017 - ESC
August 26, 2017 - ESC

In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, epigenetic regulation of gene expression in patients at high CV risk with diabetes was reviewed

SGLT-2 inhibition reduces mortality and hospitalization for HF in patients with diabetes and PAD

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Subodh Verma (St Michael's Hospital, University of Toronto, Canada)

Nov. 15, 2017 - news

AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.

hsCRP levels predict CV outcomes in type 2 diabetic patients post-ACS

Nov. 7, 2017 - Hwang YC, et al. - Diabetes Obes Metab. 2017

In post-ACS type 2 diabetic patients at high CV risk, there is a significant association between baseline hsCRP values and future CV outcomes.

Diabetes and microvascular complications predict outcomes in HFpEF

Oct. 31, 2017 - Sandesara PB et al. - Diabetes Care 2017

In the TOPCAT study, diabetes and its microvascular complications carried important prognostic information regarding adverse outcomes in HFpEF patients.

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose  a drug.

Prof. Lars Rydén describes two classes of drugs that may protect patients with type 2 diabetes from CV events. Depending on the type of patient, cardiologists can choose a drug.

Summary | Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

August 26, 2017 - Prof. Kausik Ray (London, UK)
August 26, 2017 - Prof. Kausik Ray (London, UK)

This summary by Prof Ray gives insight in the high CV risk in patiens with diabetes. Treatment options and testing of these drugs in trials were discussed, including the new antidiabetic drugs, such as empagliflozin, and other novel agents, such as the PCSK9 inhibitor evolocumab.

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017
Lecture by Prof Stephen Nicholls held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017